Cancer Institute A national cancer institute
designated cancer center

Non-Hodgkins Lymphoma Expertise

Pediatric Oncology Program

For information on our Pediatric Oncology Program please visit Lucile Packard Children's Hospital.

For Physicians: To refer a pediatric patient, please call (650) 725-1072.

Lymphoma Program physicians commonly treat non-Hodgkins lymphoma with chemotherapy and radiation therapy, and also offer advanced therapies for patients, both adults and children, who will benefit from them. These state-of-the-art treatments include: 

Stanford Research Breakthroughs

Diagnosis & Prognosis Lymphoma Program physicians lead the field in the application of genetic technology to fight cancer. For example, researchers at the Cancer Center have identified a set of six genes that may predict response to treatment in patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkins lymphoma.

This finding is the first gene-based screen to identify people who need the most aggressive therapy. Stanford researchers also recently discovered a simpler yet as accurate 2 gene signature.  This test can be done on a small piece of the tumor obtained at diagnosis. 

Patients treated by physicians in the Lymphoma Program have access to this kind of predictive genetic screening through ongoing clinical studies in both DLBCL and follicular lymphoma.

Treatments In 1994, Stanford investigators were the first to treat patients with rituximab, an antibody developed by Dr. Ronald Levy which targets the lymphoma cells. Three years later, rituximab was approved by the FDA and today is the standard therapy for almost all patients with non-Hodgkins lymphoma.

In 2011, Stanford researchers discovered a second antibody which boosts the immune response and dramatically increases the ability of rituximab to kill lymphoma.  Patients at Stanford are receiving this novel combination of antibodies through clinical trials.

Stanford investigators have cured many mice with lymphoma in the hope of finding a cure for humans.  Based on very promising mouse studies, Stanford investigators recently started a clinical trial testing a “personalized” vaccine for mantle cell lymphoma. Patients at Stanford have access to these and other state-of-the-art therapies. 

Learn more about current clinical trials.

See information on Cutaneous Lymphoma.

Stanford Medicine Resources:

Footer Links: